Trial Profile
An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms InspirAda
- Sponsors Abbott Laboratories; AbbVie
- 01 Nov 2017 Results of subgroup analysis from Inspirada presented at the 25th United European Gastroenterology Week
- 09 May 2017 Results of effect of adalimumab on extraintestinal manifestation presented at the Digestive Disease Week 2017
- 09 May 2017 Results assessing the effect of adalimumab dose escalation on various outcomes among patients (n=129) with Ulcerative Colitis in clinical practice, presented at the Digestive Disease Week 2017.